secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001104659-25-091064
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 1.01, 1.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma terminates merger with OrthoCellix, receives $4M from Moderna, expects wind-down
--------------------------------------------------------------------------------

- Moderna pays $4M one-time to eliminate all future milestones, royalties, and research costs under the 2022 collaboration; licenses become fully paid-up and perpetual.
- Merger with OrthoCellix/Ocugen terminated after OrthoCellix failed to secure $25M concurrent financing by Sept 15, 2025.
- Carisma is owed $750K termination fee and $500K expense reimbursement from OrthoCellix; OrthoCellix has not confirmed payment; Carisma intends to enforce.
- No meaningful cash expected for stockholders; company plans orderly wind-down or possible bankruptcy/liquidation absent a strategic transaction.
- Nasdaq delisting risk by Oct 7, 2025; the Hearings Panel could delist earlier given the merger was central to compliance plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925091064/0001104659-25-091064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925091064/tm2526076d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-091064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer